Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Gut microbes have ascended to prominence as key modulators of host immunity, raising the possibility that they could influence the outcome of cancer immunotherapy. Two recent studies address this question by identifying specific gut-resident bacteria as drivers of checkpoint blockade immunotherapy in pre-clinical tumor models.

Original publication

DOI

10.1016/j.ccell.2015.11.010

Type

Journal article

Journal

Cancer cell

Publication Date

12/2015

Volume

28

Pages

687 - 689

Addresses

Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7LF, UK.

Keywords

Animals, Humans, Bifidobacterium, Melanoma, Skin Neoplasms, Ventricular Dysfunction, Left, Anthracyclines, Receptors, Retinoic Acid, Antibiotics, Antineoplastic, Antibodies, Monoclonal, Antigens, CD274, Gastrointestinal Microbiome